Inspire Medical Systems, Inc. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual report, not a standalone fourth-quarter filing; quarterly results are not summarized in the supplied text.
Business context
Inspire develops and sells an implantable neurostimulation system for moderate-to-severe obstructive sleep apnea (OSA), primarily for patients unable to use or tolerate PAP/CPAP. The system monitors breathing and stimulates the hypoglossal nerve to help keep the airway open. The company reported more than 36,000 patients treated at over 1,000 medical centers. Nearly all revenue came from the Inspire system; 96.8% of FY 2022 revenue was generated in the U.S.
Financial performance and liquidity
| Metric | FY 2022 | FY 2021 | Change |
|---|---|---|---|
| Revenue | $407.9 million | $233.4 million | +74.7% |
| Gross profit | $341.7 million | $200.1 million | +70.8% |
| Gross margin | 83.8% | 85.7% | -1.9 percentage points |
| Research and development | $68.6 million | $37.4 million | +83.8% |
| Selling, general and administrative | $320.7 million | $202.6 million | +58.3% |
| Operating loss | $47.6 million | $39.9 million | Loss widened |
| Net loss | $44.9 million | $42.0 million | Loss widened 6.8% |
| Net loss per diluted share | $1.60 | $1.54 | — |
Growth was driven mainly by greater utilization, deeper penetration in existing territories, new territories, and increased physician and patient awareness; U.S. price increases also contributed. International revenue rose 4.9% to $13.0 million, while units sold outside the U.S. increased 17.0%; unfavorable foreign exchange limited reported growth.
Gross margin declined amid inflation and supply-chain costs, manufacturing-line transition costs for new silicone leads, and $2.8 million of inventory obsolescence charges related to product introductions. Advertising expense rose to $74.3 million from $47.8 million. Stock-based compensation increased to $52.0 million from $26.2 million, contributing to operating expenses.
Cash provided by operations was $11.6 million, versus $20.1 million used in FY 2021. Investing activities used $19.6 million, including $10.5 million for strategic investments and $9.1 million for property and equipment. Financing activities provided $235.1 million, principally reflecting the August stock offering. Cash and cash equivalents were $441.6 million, with $9.8 million of short-term investments; working capital was $468.8 million. The company repaid its former credit facility in August and reported no debt outstanding at year-end.
The August 2022 follow-on offering of 1.15 million shares at $215 per share generated approximately $243.8 million in net proceeds. Year-end stockholders’ equity was $496.0 million; accumulated deficit was $324.3 million.
Outlook, commentary and key risks
- Management expects FY 2023 gross margin of 83%–85%, citing higher component costs partly offset by pricing and anticipated manufacturing efficiencies. The filing does not provide a specific revenue or earnings forecast.
- Management expects continued operating losses for the foreseeable future, with higher SG&A and significant R&D spending as the company expands commercial operations and develops next-generation products.
- Management stated that year-end cash and investments, together with operating cash flows, were expected to fund operations and planned capital expenditures for at least 12 months. This depends on assumptions and is not assurance of future cash generation.
- Key risks include dependence on a single principal product; adoption and reimbursement uncertainty; competition and changing treatment options; reliance on single-source suppliers and ongoing supply-chain pressures; regulatory approval and compliance requirements; product quality, warranty and liability exposure; and cybersecurity, privacy and international expansion risks.
- COVID-19 disruptions continued to affect procedures and supply chains, although management said surgical volumes generally returned to pre-pandemic levels by the end of the first quarter of 2022 and later-year effects were less significant. No material legal proceedings were reported.
- Product and market developments included FDA approval of additional MRI scan conditions and new silicone-based leads, expansion to 905 U.S. implanting centers, and an application for pediatric use in patients with Down syndrome. FDA Breakthrough Device Designation was granted for proposed expansion of the AHI and BMI limits; this designation is not marketing approval.
Most important facts for investors to verify
- Whether rapid revenue growth can continue while operating expenses remain high and the company remains loss-making.
- Whether the expected 83%–85% FY 2023 gross margin is achieved, especially given supply, inflation and product-transition costs.
- Cash use, the impact of stock-based compensation and dilution, and the adequacy of liquidity as commercialization and R&D spending expand.
- Durability of U.S. coverage and reimbursement, progress in international reimbursement, and the effect of payer policy or procedure-payment changes.
- Supply continuity, inventory obsolescence and execution of new product launches and regulatory submissions.
- The filing reports unqualified audit opinions and effective internal controls; inventory valuation reserves were identified as a critical audit matter.